1. Scrip
  2. >>Business

AC Immune Beefs Up Neurodegenerative Diseases Pipeline

 
• By John Davis

The Swiss biotech, AC Immune, has identified further antibodies aimed at targets in neurodegenerative diseases that could complement its work in beta-amyloid and tau-based approaches to conditions like Alzheimer's disease.

A C Immune Art
Antigenic peptides on the surface of liposomes • Source: AC Immune

Antibodies targeted against pathological processes in one neurodegenerative disease might be effective in other diseases, including Alzheimer’s, according to the Swiss biotech AC Immune SA which is beefing up its early discovery pipeline with such “next-generation” antibodies.

AC Immune uses a proprietary technology, SupraAntigen, that displays antigens on the surface of liposomes and is thought to be...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.